Deveci E, Yesil M, Akinci B, Yesil S, Postaci N, Arikan E, Koseoglu M: Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin Cardiol. 2009, 32: 32-36. 10.1002/clc.20379.
WHO: World Health Report. Prevention Chronic Disease: A vital Investment. Geneva, Switzerland 2008. Accessed Apirl 2, 2010, [http://www.who.int/chp/chronic_disease_report/contents/part1.pdf]
Borch-Johnsen K: The metabolic syndrome in a global perspective. The public health impact--secondary publication. Dan Med Bull. 2007, 54: 157-159.
Wellen KE, Hotamisligil GS: Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003, 112: 1785-1788.
Ryu SY, Kim KS, Park J, Kang MG, Han MA: The association between circulating inflammatory markers and metabolic syndrome in Korean rural adults. J Prev Med Public Health. 2008, 41: 413-418. 10.3961/jpmph.2008.41.6.413.
Lindgarde F, Ercilla MB, Correa LR, Ahren B: Body adiposity, insulin, and leptin in subgroups of Peruvian Amerindians. High Alt Med Biol. 2004, 5: 27-31. 10.1089/152702904322963663.
Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007, 49: 2129-2138. 10.1016/j.jacc.2007.02.052.
Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S: C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2008, 15: 594-598. 10.1097/HJR.0b013e328308bb8b.
Ndumele CE, Pradhan AD, Ridker PM: Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr. 2006, 1: 190-196. 10.1111/j.1559-4564.2006.05538.x.
Nakanishi N, Shiraishi T, Wada M: Association between C-reactive protein and insulin resistance in a Japanese population: the Minoh Study. Intern Med. 2005, 44: 542-547. 10.2169/internalmedicine.44.542.
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol. 1999, 19: 972-978.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001, 286: 327-334. 10.1001/jama.286.3.327.
Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001, 50: 2384-2389. 10.2337/diabetes.50.10.2384.
Gelaye B, Revilla L, Lopez T, Sanchez S, Williams MA: Prevalence of metabolic syndrome and its relationship with leisure time physical activity among Peruvian adults. Eur J Clin Invest. 2009, 39: 891-898. 10.1111/j.1365-2362.2009.02191.x.
PAHO: PAN AMERICAN HEALTH ORGANIZATION. Countrywide Integrated Noncommunicable Diseases Intervention (CINDI) Programme. Accessed November 27, 2009, [http://www.paho.org/english/ad/dpc/nc/hcncindi.pdf]
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.
Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N: Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem. 2001, 47: 418-425.
Hanyu O, Yoshida J, Abe E, Hirayama S, Miyake K, Aizawa Y, Miida T: High- sensitivity CRP reflects insulin resistance in smokers. J Atheroscler Thromb. 2009, 16: 560-567.
Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-1143. 10.1161/hc0902.104353.
Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999, 340: 448-454. 10.1056/NEJM199902113400607.
Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S: Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol. 1999, 163: 3957-3962.
Fukuchi Y, Miura Y, Nabeno Y, Kato Y, Osawa T, Naito M: Immunohistochemical detection of oxidative stress biomarkers, dityrosine and N(epsilon)- (hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic lesions. J Atheroscler Thromb. 2008, 15: 185-192.
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010, 375: 132-140. 10.1016/S0140-6736(09)61717-7.
Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E: Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001, 47: 444-450.
Willett WC, Dietz WH, Colditz GA: Guidelines for healthy weight. N Engl J Med. 1999, 341: 427-434. 10.1056/NEJM199908053410607.
Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX: Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr. 2008, 87: 1212-1218.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003, 107: 499-511. 10.1161/01.CIR.0000052939.59093.45.